IRCT20100119003106N48
Completed
未知
Double-Center, Randomized, Double-Blind, Placebo-Controlled Study on the Effects of Postbiotic Supplementation with Lactobacillus rhamnosus CRL 1505 and Lactobacillus johnsonii La1 (La1), with a Focus on IL-10; Impact on Upper Respiratory Tract Infection and Vaginitis Incidence
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Islamic Azad University
- Enrollment
- 150
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •adult men or women between 18 and 65 years old who enter the study and have fully understood the risks and potential benefits of participating in the study
- •and before entering the study, consent forms They have signed it knowingly.
Exclusion Criteria
- •Unwillingness to continue or participate in the study
- •Diagnosis of immunodeficiency due to any diagnosed chronic disease
- •Gastrointestinal ulcer
- •Liver and kidney dysfunction
- •Human immunodeficiency virus
- •Autoimmune disorders
- •Malignancy, or any history of malignancy
- •Any diagnosis of respiratory diseases with cold or flu\-like symptoms
- •Severe diseases such as asthma and severe allergies
- •Pregnancy, breastfeeding
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Single center, double-blind, randomized, placebo-controlled, two-period/two-treatment crossover study investigating the effect of miglustat on the nasal potential difference in patients with cystic fibrosis homozygous for the F508del mutatioCystic fibrosis homozygous for the F508del mutationMedDRA version: 9.1Level: LLTClassification code 10011762Term: Cystic fibrosisEUCTR2008-002352-20-BEActelion Pharmaceuticals Ltd
Completed
Not Applicable
Single-center, double-blind, randomized, placebo-controlled, single-ascending dose and food interaction study to investigate the tolerability, safety, pharmacokinetics, and pharmacodynamics of ACT-389949 in healthy male subjectsAcute inflammation1004795410027665NL-OMON35247Actelion Pharmaceuticals64
Completed
Not Applicable
Clinical trial for evaluation of efficacy on cognitive function of MT104Mental and behavioural disordersKCT0006499Kyung Hee University Hospital86
Not yet recruiting
Not Applicable
Clinical studies to evaluate the efficacy and safety of oxygen / ozone therapy devices for patients suffering from pain due to lumbar disc herniatioKCT0003917Healthwell Medical50
Active, not recruiting
Phase 1
Refractory abdominal fluid (ascites) in patients with liver cirrhosis, and the potential treatment with 48 hours infusion of ularitide; a salt and water excreting peptide.iver cirrhosis with refractory ascites.MedDRA version: 20.0Level: LLTClassification code 10024667Term: Liver cirrhosisSystem Organ Class: 100000004871MedDRA version: 20.0Level: PTClassification code 10003445Term: AscitesSystem Organ Class: 10017947 - Gastrointestinal disordersTherapeutic area: Diseases [C] - Symptoms and general pathology [C23]EUCTR2019-002268-28-DKDepartment of Hepatology and Gastroenterology, Aarhus University Hospital38